EUVIMEDEUVIMED entdecken
Crossref

Trojan Horse‐Inspired Biomimetic Lipoprotein Nanocarrier for Noninvasive Anti‐VEGF Therapy of Ocular Fundus Neovascularization

Lin Chen iD, Chen Fan, Antian Wang, Chenyun Zhang, Peiying Li, Renhe Yu, Kexin Shi, Minghao Chen, Shiqi Yang, Wen Shi, Qingxiang Song, Gan Jiang und 3 weitere

Advanced Materials · 2025-11 · 37 (44)

DOI: 10.1002/adma.202508104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 28.08.2025. Verfasst von Lin Chen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor A, Cell-Penetrating Peptides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 83 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Shanghai Municipal Education Commission, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathological neovascularization is a major cause of vision loss in various ischemic and inflammatory ocular fundus diseases, with current anti‐VEGF therapies requiring invasive and frequent intravitreal injections. In this study, a Trojan horse‐inspired biomimetic lipoprotein nanocarrier (A‐PA‐αCPP) is developed for noninvasive anti‐VEGF therapy via topical administration. Utilizing phosphatidic acid (PA), specifically 1,2‐dioleoyl‐sn‐glycero‐3‐phosphate (DOPA), as the sole phospholipid, the nanocarrier enables electrostatic tethering of aflibercept, with a cell‐penetrating peptide (CPP)‐functionalized apoA1 mimetic peptide (αCPP) incorporated through self‐assembly. Molecular dynamics simulations and intermolecular interaction experiments confirm effective PA–protein interactions and αCPP incorporation. The nanocarrier demonstrates high encapsulation efficiency, size uniformity, and long‐term stability. It enhances transcellular and paracellular transport by promoting cellular uptake, bypassing lysosomal degradation, and modulating tight junctions. When topically administered, A‐PA‐αCPP efficiently delivers to the posterior segment via corneal and conjunctival–scleral–choroidal pathways. In a laser‐induced choroidal neovascularization (CNV) mouse model, A‐PA‐αCPP eye drops show therapeutic efficacy comparable to a single intravitreal injection, while maintaining excellent ocular and systemic biocompatibility. This biomimetic platform highlights the potential of PA‐mediated protein binding in nanocarrier design, offering a promising strategy for home‐based anti‐VEGF therapy and extending the potential to other protein‐based therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor ACell-Penetrating PeptidesBiomimetic MaterialsLipoproteinsHuman Umbilical Vein Endothelial CellsDrug CarriersAngiogenesis InhibitorsNanoparticlesHumans

Stichwörter der Autor:innen

anti‐VEGF therapycell‐penetrating peptideslipoprotein nanocarriersnoninvasive drug deliveryocular fundus neovascularizationphosphatidic acid

Substanzen

Vascular Endothelial Growth Factor ALipoproteinsCell-Penetrating PeptidesDrug CarriersAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
  • National Clinical Research Center for Eye Diseases, Shanghai, 200080, China.
  • Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, 200080, China.
  • Department of Pharmacology and Chemical Biology, Collaborative Innovation Center for Clinical and Translational Science by Chinese Ministry of Education & Shanghai, Shanghai Jiao Tong University School of Medicine, Shan…

ORCID-Profile: Lin Chen, Xiaoling Gao, Xiaodong Sun

Förderung

  • National Key Research and Development Program of China
  • Shanghai Municipal Education Commission
  • Science and Technology Commission of Shanghai Municipality
  • National Natural Science Foundation of China
  • Shanghai Science and Technology Development Foundation
  • Innovation Program of Shanghai Municipal Education Commission
  • Shanghai Excellent Youth Medical Professionals Training Program

Zitieren

APA

Chen, L., Fan, C., Wang, A., Zhang, C., Li, P., Yu, R., Shi, K., Chen, M., Yang, S., Shi, W., Song, Q., Jiang, G., Huang, Y., Gao, X., & Sun, X. (2025). Trojan Horse‐Inspired Biomimetic Lipoprotein Nanocarrier for Noninvasive Anti‐VEGF Therapy of Ocular Fundus Neovascularization. Advanced Materials, 37(44). https://doi.org/10.1002/adma.202508104

Vancouver

Chen L, Fan C, Wang A, Zhang C, Li P, Yu R, et al. Trojan Horse‐Inspired Biomimetic Lipoprotein Nanocarrier for Noninvasive Anti‐VEGF Therapy of Ocular Fundus Neovascularization. Advanced Materials. 2025;37(44). doi:10.1002/adma.202508104

BibTeX
@article{Chen2025,
  author = {Chen, Lin and Fan, Chen and Wang, Antian and Zhang, Chenyun and Li, Peiying and Yu, Renhe and Shi, Kexin and Chen, Minghao and Yang, Shiqi and Shi, Wen and Song, Qingxiang and Jiang, Gan and Huang, Yukun and Gao, Xiaoling and Sun, Xiaodong},
  title = {Trojan Horse‐Inspired Biomimetic Lipoprotein Nanocarrier for Noninvasive Anti‐VEGF Therapy of Ocular Fundus Neovascularization},
  journal = {Advanced Materials},
  year = {2025},
  volume = {37},
  number = {44},
  doi = {10.1002/adma.202508104}
}
Kostenlos starten →